Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000802186 | SCV000942004 | benign | Nemaline myopathy 2 | 2023-12-25 | criteria provided, single submitter | clinical testing | |
Al Jalila Children’s Genomics Center, |
RCV000802186 | SCV001984169 | uncertain significance | Nemaline myopathy 2 | 2019-12-29 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003141800 | SCV003814117 | uncertain significance | not provided | 2023-12-18 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004702429 | SCV005202492 | uncertain significance | not specified | 2024-07-12 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.19325G>A (p.Arg6442Gln) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 248858 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in NEB causing Nemaline Myopathy 2 (0.0001 vs 0.0035), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.19325G>A in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 647634). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV000802186 | SCV001461661 | uncertain significance | Nemaline myopathy 2 | 2020-01-24 | no assertion criteria provided | clinical testing |